Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2010

View Archived Issues

Phase IIa data disclosed on tideglusib in Alzheimer's disease

Novartis reviews second quarter of 2010

EVP-0015962 improves cognitive deficit in mouse model of Alzheimer's disease

PDIP-38 is a candidate biomarker for progression of HPV-16-associated cervical dysplasia

Insulin degludec improves glucemic control in phase II trials in type 1 and 2 diabetes

Drug-targetable rearrangements of RAF kinase pathway members identified in prostate cancer

Repros Therapeutics to start low-dose study of Proellex

Tarsa advances phase III oral calcitonin trial in postmenopausal osteoporosis

Enrollment begins in phase II MM-121 trial in breast cancer

NACI updates recommendations on rotavirus vaccination in Canada

University of Michigan claims new STAT-3 inhibitors

AiCuris discloses new anti-HIV agents

Algeta concludes manufacture and supply agreements for alpharadin

S/GSK-1265744 is active against RAL-resistant HIV isolates in vitro

Fresenius Medical Care expands its dialysis products business

FDA grants CBLB-502 fast track status for acute radiation syndrome

DSMB recommends completion of phase II FV-100 trial in shingles

NPS Pharma advances phase III trial of teduglutide in short bowel syndrome

ConjuChem Biotechnologies files for bankruptcy

CP-404 successfully completes pilot phase I study for obesity

CHMP concludes topical ketoprofen has positive benefit-to-risk balance

Euthymics Bioscience acquires DOV Pharma and continues EB-1010 development

MDRNA shareholders approve Cequent acquisition and name change to Marina Biotech

Korean scientists discover new cyclic penta-depsipeptides

Sirtris Pharmaceuticals describes new SIRT modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...